Yi Ariel Liu

Dr. Yi Ariel Liu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2020 in Histopathology
Verified
Journal Article
Closed access
PDF file
YLYi Ariel Liu
Yi Ariel Liu
JJJennifer X Ji
Jennifer X Ji
NANoorah Almadani
Noorah Almadani
RCRichard I Crawford
Richard I Crawford
CGC Blake Gilks
C Blake Gilks
LHLynn Hoang
Lynn Hoang

15 March 2024 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
YLYi Ariel Liu
Yi Ariel Liu
Phyu P AungPhyu P Aung
Phyu P Aung
YWYunyi Wang
Yunyi Wang
JNJing Ning
Jing Ning
PNPriyadharsini Nagarajan
Priyadharsini Nagarajan
Woo Cheal ChoWoo Cheal Cho
Woo Cheal Cho
Background: Although trichorhinophalangeal syndrome type 1 (TRPS1) was initially thought to be highly sensitive and specific for carcinomas and mesenchymal tumors of mammary origin, more recent data suggest its expression is not limited to breast neoplasms but also can be seen in other cutaneous neoplasms, such as extramammary Paget disease and squamous cell carcinoma (SCC) in situ.Methods: Two-hundred cases of non-melanocytic cutaneous neoplasm, including basal cell carcinomas (BCCs) (n = 41), SCCs (n = 35), Merkel cell carcinomas (MCCs) (n = 25), and adnexal neoplasms (n = 99), were tested for TRPS1 expression using a monoclonal anti- TRPS1 rabbit anti-human antibody.Results: TRPS1 expression was present in almost all cases of SCC (94%), with a median H-score of 200, while it was either absent or only focally present in most BCCs (90%), with a median H-score of 5. The difference between BCCs and SCCs in H-score was significant (p < .001). All MCCs (100%) lacked TRPS1 expression. TRPS1 expression was frequently seen in most adnexal neoplasms, benign and malignant, in variable intensity and proportion but was consistently absent in apocrine carcinomas. All endocrine mucin-producing sweat gland carcinomas (EMPSGCs) (100%, 6/6) showed diffuse and strong TRPS1 immunoreactivity, with a median H-score of 300, which was significantly different (p < .001) than that of BCCs.Conclusions: Our study shows that TRPS1 may be an effective discriminatory marker for BCCs and SCCs. It also has a role in distinguishing BCCs from EMPSGCs.

15 July 2024 in Dermatopathology
Verified
Journal Article
Open access
PDF file
MKMoon Joo Kim
Moon Joo Kim
YLYi Ariel Liu
Yi Ariel Liu
YWYunyi Wang
Yunyi Wang
JNJing Ning
Jing Ning
Woo Cheal ChoWoo Cheal Cho
Woo Cheal Cho
Although extensively studied in cutaneous epithelial neoplasms, the TRPS1 immunoreactivity in cutaneous mesenchymal neoplasms and tumors of uncertain differentiation (CMNTUDs), such as atypical fibroxanthoma (AFX), remains largely unexplored. We assessed TRPS1 immunoreactivity in 135 CMNTUDs, comprising 46 fibrohistiocytic/fibroblastic tumors, 28 vascular tumors, 24 peripheral nerve sheath tumors (PNSTs), 21 tumors of uncertain differentiation, and 16 smooth muscle tumors. Additionally, we included selected cases of melanoma with spindled cell morphology or desmoplastic features (n = 9) and sarcomatoid squamous cell carcinoma (SSCC) (n = 5) to compare TRPS1 expression patterns with those of AFX. TRPS1 expression was prevalent in dermatofibromas (24/24), leiomyomas (8/8), AFXs/pleomorphic dermal sarcoma (PDS) (20/21), dermatofibrosarcomas protuberans (14/22), and leiomyosarcomas (6/8). It was uncommon in angiosarcomas (3/20), Kaposi sarcomas (2/8), and neurofibromas (5/17) and absent in perineuriomas (0/2). AFXs/PDS exhibited the highest median H-score of 240, contrasting with minimal TRPS1 immunoreactivity in vascular neoplasms and PNSTs, with median H-scores consistently below 10. Significant differences in H-score were observed between AFXs/PDS and angiosarcomas (p < 0.001), melanomas (p < 0.001), and leiomyosarcomas (p = 0.029). However, no significant difference was found compared to SSCCs, suggesting limited discriminatory power of TRPS1 in this context. This study sheds light on TRPS1 expression patterns in a subset of CMNTUDs, extending beyond prior studies primarily focused on epithelial tumors, while underscoring potential pitfalls associated with TRPS1 immunohistochemistry.

7 January 2021 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
YLYi Ariel Liu
Yi Ariel Liu
AFAlexander J. Finn
Alexander J. Finn
ASAntonio Subtil
Antonio Subtil

27 April 2020 in Fetal and Pediatric Pathology
Verified
Journal Article
Closed access
YLYi Ariel Liu
Yi Ariel Liu
CCChieko Chijiwa
Chieko Chijiwa
CDChristopher P. Dunham
Christopher P. Dunham
DJDouglas H. Jamieson
Douglas H. Jamieson
ASAlfonso Solimano
Alfonso Solimano
ALAnna Lee
Anna Lee
Background: Arthrochalasia type Ehlers-Danlos Syndrome (EDS) is a connective tissue disease characterized by severe generalized joint hypermobility, congenital bilateral hip dislocations, and recurrent joint subluxations and dislocations. Only one study has reported bone fragility resulting in fractures. The genetic abnormality underlying this disorder is a variant in the COL1A1 gene causing entire or partial loss of exon 6, resulting in defective type 1 collagen synthesis. Case Report: We report a female infant born at 35 weeks of gestation presenting with pathologic skull fracture following vaginal delivery. Genetic testing revealed a pathogenic variant in the COL1A1 gene (c.472-1G > C), consistent with arthrochalasia type EDS, reported previously. Conclusion: This report adds pathologic fractures to the phenotypic breadth of this type of EDS and reinforces the importance of including the condition on the differential diagnosis when early onset non-accidental injury or trauma is being considered.

25 April 2023 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
TSToby A. Schmitt
Toby A. Schmitt
YLYi Ariel Liu
Yi Ariel Liu
RCRichard I. Crawford
Richard I. Crawford